Meets criteria for CIDP based on EAN/PNS Task Force CIDP guidelines, second revision (2021)
Has either typical CIDP or 1 of the following CIDP variants: motor CIDP (including motor-predominant CIDP), multifocal CIDP (also known as Lewis-Sumner syndrome), focal CIDP, or distal CIDP
Has residual disability and active disease
Has not received previous treatment for CIDP; or has stopped receiving CIDP treatment; or is receiving CIDP treatment (pulsed or oral corticosteroids, immunoglobulins, PLEX, or FcRn inhibitors)
Participants already receiving CIDP treatment will have to discontinue their CIDP treatment before first IMP administration and must be willing to switch to the study IMP
You may not be if
Meets the criteria for possible CIDP based on EAN/PNS Task Force CIDP guidelines, second revision (2021)
Sensory CIDP (including sensory-predominant CIDP)
Polyneuropathy of other causes
Clinical diagnosis of systemic lupus erythematosus (SLE)
Use of other long-acting immunomodulatory treatment or prior treatment (at any time) with total lymphoid irradiation or bone marrow transplantation
Clareo Health | A Study to Assess the Efficacy and Safety of Empasiprubart in Adults With CIDP
